EP1395260A1 - Verwendung des opioid-antagonisten naltrexon zur vorbeugung und kontrolle der durch opioide verursachten nebeneffekte - Google Patents

Verwendung des opioid-antagonisten naltrexon zur vorbeugung und kontrolle der durch opioide verursachten nebeneffekte

Info

Publication number
EP1395260A1
EP1395260A1 EP02726358A EP02726358A EP1395260A1 EP 1395260 A1 EP1395260 A1 EP 1395260A1 EP 02726358 A EP02726358 A EP 02726358A EP 02726358 A EP02726358 A EP 02726358A EP 1395260 A1 EP1395260 A1 EP 1395260A1
Authority
EP
European Patent Office
Prior art keywords
naltrexone
side effects
effects caused
morphine
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02726358A
Other languages
English (en)
French (fr)
Inventor
Roberto Valducci
Tiziano Alighieri
Serozh Avanessian
William Raffaeli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valpharma SpA
Original Assignee
Valpharma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valpharma SpA filed Critical Valpharma SpA
Publication of EP1395260A1 publication Critical patent/EP1395260A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
EP02726358A 2001-05-02 2002-05-02 Verwendung des opioid-antagonisten naltrexon zur vorbeugung und kontrolle der durch opioide verursachten nebeneffekte Withdrawn EP1395260A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI20010907 2001-05-02
IT2001MI000907A ITMI20010907A1 (it) 2001-05-02 2001-05-02 Impiego di antagonisti oppioidi per la prevenzione ed il controllo degli effetti collaterali prodotti dagli oppioidi
PCT/IB2002/001473 WO2002087582A1 (en) 2001-05-02 2002-05-02 Use of the opioid antagonist naltrexone to prevent and control side effects caused by opioids

Publications (1)

Publication Number Publication Date
EP1395260A1 true EP1395260A1 (de) 2004-03-10

Family

ID=11447580

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02726358A Withdrawn EP1395260A1 (de) 2001-05-02 2002-05-02 Verwendung des opioid-antagonisten naltrexon zur vorbeugung und kontrolle der durch opioide verursachten nebeneffekte

Country Status (5)

Country Link
EP (1) EP1395260A1 (de)
IT (1) ITMI20010907A1 (de)
RU (1) RU2003135201A (de)
WO (1) WO2002087582A1 (de)
ZA (1) ZA200309333B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US20060063792A1 (en) * 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US9056054B2 (en) 2009-06-25 2015-06-16 Elite Laboratories, Inc. Abuse resistant oral dosage forms
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
MX2021000908A (es) 2018-07-23 2021-06-08 Trevi Therapeutics Inc Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010006967A1 (en) * 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
PL193273B1 (pl) * 1997-12-22 2007-01-31 Euro Celtique Sa Postać dawkowania doustnego
JP2003535833A (ja) * 2000-06-09 2003-12-02 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア ナルブフィンとオピオイドアンタゴニストを使用した疼痛の処置法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02087582A1 *

Also Published As

Publication number Publication date
ITMI20010907A0 (it) 2001-05-02
ZA200309333B (en) 2004-02-17
WO2002087582A1 (en) 2002-11-07
RU2003135201A (ru) 2005-03-27
ITMI20010907A1 (it) 2002-11-02

Similar Documents

Publication Publication Date Title
RU2239417C2 (ru) Опиоидные анальгетики с контролируемым высвобождением активных веществ
US9655855B2 (en) Matrix for sustained, invariant and independent release of active compounds
CA2273353C (en) Galenic composition containing opioid antagonists
JPH0469605B2 (de)
WO2011117306A1 (en) Double-layer pharmaceutical formulations containing opioid agonists and antagonists
SK14282000A3 (sk) Farmaceutický prostriedok na liečenie závislosti od alkoholu a drog obsahujúci opiátového antagonistu a modulátor súhrnu nmda receptorov
HRP20010706A2 (en) Tolperison-containing, pharmaceutical preparation for oral administration
WO2002087582A1 (en) Use of the opioid antagonist naltrexone to prevent and control side effects caused by opioids
SK652000A3 (en) Orally applicable composition of analgesics with controlled release of an active substance
JPH0428685B2 (de)
EP1897544A1 (de) Opioid agonist und antagonisten Kombinationen
JP4933265B2 (ja) フルピルチン及びトラマドールの組み合わせ
EP2130539A1 (de) Therapeutische tablette für post-herpes-neuralgie und verfahren zur behandlung von post-herpes-neuralgie
AU2002256838A1 (en) Use of the opioid antagonist naltrexone to prevent and control side effects caused by opioids
JP2001097856A (ja) 鎮咳剤
US20030139396A1 (en) Method of treatment
EP0901376A1 (de) Melatonin in kombination mit analgetika
JP2019535758A (ja) リドカイン無効状態および低カリウム血症状態の治療のための療法
RU2183116C1 (ru) Фармацевтическая композиция, обладающая болеутоляющим, противовоспалительным, антипиретическим и спазмолитическим действием
MXPA02011611A (es) Combinacion de sustancia activa que contiene un compuesto con efecto opioide y por lo menos un compuesto adicional de formula i.
WO2004026291A1 (fr) Formulations orales d'ibuprofene et de tramadol, methodes de preparation de ces dernieres
KR20020063180A (ko) 물질 탐닉 치료방법
WO2003103679A1 (en) Use of devazepide in combination with an opioid analgesic for potentiating the effect of the analgesic
Cornish What long-acting oral opioid products are currently available in Canada?
Naspitz et al. Theophylline serum levels in children with bronchial asthma after administration of slow release theophylline as open or closed capsules

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20060123